World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Immunology

D-Index
163
Citations
110228
World Ranking
69
National Ranking
47

Douglas D. Richman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Douglas D. Richman sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 651 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Douglas D. Richman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Douglas D. Richman sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 163 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 1999 - Fellow of the American Association for the Advancement of Science (AAAS)
  • 1984 - Fellow of John Simon Guggenheim Memorial Foundation
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Douglas D. Richman is affiliated with the University of California, San Diego in the United States. Their research primarily focuses on medicine, with significant work in immunology and microbiology. The scientist's subfields include infectious diseases, virology, emergency medicine, epidemiology, and immunology.

The main topics addressed in their research encompass HIV research and treatment, HIV/AIDS drug development and treatment, HIV/AIDS research and interventions, HIV-related health complications and treatments, COVID-19 clinical research studies, Pneumocystis jirovecii pneumonia detection and treatment, and SARS-CoV-2 and COVID-19 research.

Douglas D. Richman's recent publications include:

  • 2025 update of the drug resistance mutations in HIV-1, 2025, PubMed
  • Recommendations for measuring HIV reservoir size in cure-directed clinical trials, 2020, Nature Medicine
  • Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society-USA Panel, 2020, UNC Libraries
  • Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection, 2023, Nature Communications
  • Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study, 2020, PLoS Medicine

The scientist has collaborated frequently with several coauthors, including Nicolas Chomont, Huldrych F. Günthard, Bonnie J. Howell, Janet D. Siliciano, and Davey M. Smith.

Douglas D. Richman's work has been published in a range of scholarly venues, with notable contributions in UNC Libraries, Nature Communications, PLoS Medicine, Clinical Infectious Diseases, and Journal of Clinical Microbiology.

The scientist has received recognition such as being named a Fellow of the American Association for the Advancement of Science (AAAS) in 1999 and a Fellow of the John Simon Guggenheim Memorial Foundation in 1984. They are also a member of the Association of American Physicians.

Best Publications

  • The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.

    Margaret A Fischl;D. D. Richman;M. H. Grieco;M. S. Gottlieb

  • Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

    Diana Finzi;Monika Hermankova;Theodore Pierson;Lucy M. Carruth

  • Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

    Joseph K. Wong;Marjan Hezareh;Huldrych F. Günthard;Diane V. Havlir

  • Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    R M Gulick;J W Mellors;D Havlir;J J Eron

  • HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

    Brendan A. Larder;Graham Darby;Douglas D. Richman

  • Update of the Drug Resistance Mutations in HIV-1.

    Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Huldrych F Gunthard

  • Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

    Victor Appay;P. Rod Dunbar;Margaret Callan;Paul Klenerman

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Rapid evolution of the neutralizing antibody response to HIV type 1 infection

    Douglas D. Richman;Terri Wrin;Susan J. Little;Christos J. Petropoulos

  • Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection: A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter

    Paul A. Volberding;Stephen W. Lagakos;Matthew A. Koch;David K. Booth

  • Antiretroviral-Drug Resistance among Patients Recently Infected with HIV

    Susan J. Little;Sarah Holte;Jean Pierre Routy;Eric S. Daar

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

    N. M. Archin;A. L. Liberty;A. D. Kashuba;S. K. Choudhary

  • 2011 update of the drug resistance mutations in HIV-1.

    Johnson Va;Calvez;Günthard Hf;Paredes R

  • Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication.

    John C. Guatelli;Kristina M. Whitfield;Deborah Y. Kwoh;Kevin J. Barringer

  • Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants

    Mark Roman;Elena Martin-Orozco;Justin S. Goodman;Minh-Duc Nguyen

  • HIV-Specific Cd8+T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function

    Victor Appay;Douglas F. Nixon;Sean M. Donahoe;Geraldine M.A. Gillespie

  • Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

    Z. Q. Zhang;T. Schuler;M. Zupancic;Stephen W Wietgrefe

  • The challenge of finding a cure for HIV infection.

    Douglas D. Richman;David M. Margolis;Martin Delaney;Warner C. Greene

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

Frequent Co-Authors

Davey M. Smith
Davey M. Smith University of California, San Diego
Susan J. Little
Susan J. Little University of California, San Diego
Joseph K. Wong
Joseph K. Wong University of California, San Francisco
Diane V. Havlir
Diane V. Havlir University of California, San Francisco
Huldrych F. Günthard
Huldrych F. Günthard University of Zurich
Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Sergei L. Kosakovsky Pond
Sergei L. Kosakovsky Pond Temple University
Margaret A. Fischl
Margaret A. Fischl University of Miami
John C. Guatelli
John C. Guatelli University of California, San Diego
Stephen A. Spector
Stephen A. Spector University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens doors to diverse healthcare careers, including many that blend clinical practice with research. For those interested in expanding their scope in patient care, enrolling in a nurse practitioner accelerated program can be a strategic next step. These programs are designed to build advanced clinical skills quickly, making them ideal for professionals who want to elevate their roles in healthcare settings.

If you’re new to nursing but want to transition into the field, several online RN programs for non nurses provide flexible pathways to obtain a registered nurse license without traditional campus attendance. These programs cater particularly well to career changers balancing other commitments.

For individuals seeking quicker entry into nursing, exploring easiest accelerated nursing programs to get into can offer practical options that prioritize accessibility while maintaining educational quality. Similarly, those interested in foundational nursing roles might consider LPN schools easy to get into, enabling a faster start in patient care professions.

These related online degrees complement an Immunology background by providing clinical expertise and expanding career opportunities across healthcare fields.

Best Scientists Citing Douglas D. Richman

Trending Scientists

Recently Published Articles